RNF19A and cancer: To further test whether RNF19A has a role in the DDR, we knocked down RNF19A and found cancer cells were more resistant to DNA-damaging agents, including Olaparib, Cisplatin, and IR (Fig. 1c–e), whereas ectopically expressed WT RNF19A reversed this phenomenon (Supplementary Fig. 1e–g).